Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.

Article  CAS  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Cabasag CJ, Arnold M, Rutherford M, Bardot A, Ferlay J, Morgan E, et al. Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study. Br J Cancer. 2022;126:1774–82.

Article  PubMed  PubMed Central  Google Scholar 

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Prim. 2016;2:16022.

Article  PubMed  Google Scholar 

Feng Y, Cai L, Pook M, Liu F, Chang C-H, Mouti MA, Nibhani R, Militi S, Dunford J, Philpott M, Fan Y, Fan G-C, Liu Q, Qi J, Wang C, Hong W, Morgan H, Wang M, Sadayappan S, Jegga AG, Oppermann U, Wang Y, Huang W, Jiang LPS. BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma. Gastroenterology. 2023;166:139–54.

Article  PubMed  Google Scholar 

Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. 2021;48:10–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akkapeddi P, Hattori T, Khan I, Glasser E, Koide A, Ketavarapu G, et al. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors. Proc Natl Acad Sci. 2023;120: e2302485120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahadevan KK, LeBleu VS, Ramirez EV, Chen Y, Li B, Sockwell AM, et al. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Dev Cell. 2023;58:1562-1577.e8.

Article  CAS  PubMed  Google Scholar 

Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell. 2023;41:1606-1620.e8.

Article  CAS  PubMed  Google Scholar 

Pan M, Jiang C, Zhang Z, Achacoso N, Alexeeff S, Solorzano AV, et al. TP53 gain-of-function and non–gain-of-function mutations are associated with differential prognosis in advanced pancreatic ductal adenocarcinoma. JCO Precis Oncol. 2023;7: e2200570.

Article  PubMed  Google Scholar 

Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci. 2010;107:246–51.

Article  CAS  PubMed  Google Scholar 

Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527–40.

Article  PubMed  PubMed Central  Google Scholar 

Lennon AM, Wolfgang CL, Canto MI, Klein AP, Herman JM, Goggins M, et al. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res. 2014;74:3381–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foster DS, Jones RE, Ransom RC, Longaker MT, Norton JA. The evolving relationship of wound healing and tumor stroma. JCI Insight. 2018;3: e99911.

Article  PubMed  PubMed Central  Google Scholar 

Dvorak HF. Tumors: wounds that do not heal-redux. Cancer Immunol Res. 2015;3:1–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol. 2019;12:126.

Article  PubMed  PubMed Central  Google Scholar 

Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619:707–15.

Article  CAS  PubMed  Google Scholar 

Ramezani F, Panahi Meymandi AR, Akbari B, Tamtaji OR, Mirzaei H, Brown CE, et al. Outsmarting trogocytosis to boost CAR NK/T cell therapy. Mol Cancer. 2023;22:183.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uslu U, Da T, Assenmacher C-A, Scholler J, Young RM, Tchou J, et al. Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma. Sci Adv. 2023;9:02526.

Article  Google Scholar 

Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang W-T, Vogl DT, Waxman AJ, et al. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discov. 2023;4:118–33.

Article  CAS  PubMed  Google Scholar 

Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy—current perspectives and future directions. Cell. 2023;186:1652–69.

Article  CAS  PubMed  Google Scholar 

Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farhangnia P, Mollazadeh Ghomi S, Mollazadehghomi S, Delbandi A-A. Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment. Cham: Springer; 2023. p. 1–54.

Google Scholar 

Zheng L, Ding D, Edil BH, Judkins C, Durham JN, Thomas DL II, et al. Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma. Clin Cancer Res. 2021;27:1278–86.

Article  CAS  PubMed  Google Scholar 

Pihlak R, Weaver JMJ, Valle JW, McNamara MG. Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy. Cancers (Basel). 2018;10:17.

Article  PubMed  Google Scholar 

Riquelme E, Maitra A, McAllister F. Immunotherapy for pancreatic cancer: more than just a gut feeling. Cancer Discov. 2018;8:386–8.

Article  PubMed  Google Scholar 

Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, von Strandmann EP, et al. The immune microenvironment in pancreatic cancer. Int J Mol Sci. 2020;21:7307.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, et al. Pancreatic cancer and immunotherapy: a clinical overview. Cancers (Basel). 2021;13:4138.

Article  CAS  PubMed  Google Scholar 

Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021;14:14.

Article  PubMed  PubMed Central  Google Scholar 

Chen J, Xiao-Zhong G, Qi X-S. Clinical outcomes of specific immunotherapy in advanced pancreatic cancer: a systematic review and meta-analysis. J Immunol Res. 2017;2017:8282391.

Article  PubMed